Chromium is an inexpensive trace mineral that helps insulin control blood sugar. Its most credible benefits are modest improvements in blood sugar and insulin resistance in people with elevated blood sugar, type 2 diabetes, or polycystic ovary syndrome. Weight-loss claims are not well supported, and metabolically healthy adults see little benefit. It is well tolerated at typical doses. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting blood glucose | 70–85 mg/dL | Primary target of chromium's insulin effect |
| Hemoglobin A1c (HbA1c) | Below 5.4% | Reflects ~3-month average blood sugar; tracks durable change |
| Fasting insulin | Below 5–6 µIU/mL | Detects insulin resistance where chromium is most likely to help |
| HOMA-IR | Below 1.5 | Estimates insulin resistance from fasting glucose and insulin |
| Triglycerides | Below 100 mg/dL (optimal below 70) | Captures possible lipid benefit and insulin resistance |
| Serum ferritin | 50–150 ng/mL | Chromium competes with iron transport; guards against iron interference |
| Creatinine / eGFR | eGFR above 90 mL/min | Kidney safety given rare high-dose injury reports |
| Alanine aminotransferase (ALT) | Below 25 U/L (women), below 30 U/L (men) | Liver safety given rare high-dose injury reports |
Cadence: Baseline, then recheck glycemic and lipid markers at ~12 weeks; on antidiabetic medication check blood sugar several times weekly early on; every 6–12 months thereafter, with periodic kidney and liver checks for long-term or higher-dose use.